Top

Journal of Neurology

Published in:

Open Access 01-05-2020 | Stroke | Original Communication

Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography

Authors: Angela Rosenbohm, Dominik Buckert, Jan Kassubek, Wolfgang Rottbauer, Albert C. Ludolph, Peter Bernhardt

Published in: Journal of Neurology | Issue 5/2020

Abstract

Objective

To investigate cardiac involvement in patients with sporadic inclusion body myositis (IBM) by cardiac magnetic resonance tomography (CMR).

Methods

A case series of 20 patients with IBM underwent basic cardiac assessment and CMR including functional imaging, native and contrast-enhanced T1-weighted, and late gadolinium enhancement (LGE) imaging.

Results

All IBM patients reported no cardiac symptoms. Echocardiography was normal in 16/17 IBM patients. In CMR, IBM patients had normal ejection fractions (mean LVEF 63 ± 7%) and ventricular mass. They had reduced left (mean 55 versus 88 ml) and right ventricular stroke volumes (mean 54 versus 86 ml) and increased early myocardial enhancement (pathological T1 Ratio in 44% versus 5%), as compared to age- and gender-matched controls. Since arterial hypertension was more often observed in IBM patients, hypertensive heart disease can also be causative for these changes. Late gadolinium enhancement did not differ statistically from healthy controls. There was no apparent association between elevated biomarkers, echocardiography and CMR.

Conclusion

CMR revealed subtle changes in cardiac geometry and tissue characterization in IBM patients when compared to a gender- and age-matched control group. Findings in CMR indicated a higher extent of diffuse myocardial fibrosis as well as smaller left ventricular stroke volumes. These alterations may be due to a higher prevalence of arterial hypertension in the IBM cohort.

Dalakas MC (1991) Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 325:487–1498CrossRef

Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 373(4):393–394CrossRef

Askanas V, Engel WK, Nogalska A (2015) Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta 1852:633–643CrossRef

Dalakas MC (2006) Sporadic inclusion body myositis—diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2:437–447CrossRef

Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA (2011) A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain 134:3167–3175CrossRef

Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, Stojkovic T, Leite MI, Allenbach Y, Herson S, Brady S, Eymard B, Hilton-Jones D (2011) Long-term observational study of sporadic inclusion body myositis. Brain 134:3176–3184CrossRef

Rose MR, ENMC IBM Working Group (2013) In: 188th ENMC International Workshop: inclusion body myositis, 2–4 December 2011, Naarden, The Netherlands. Neuromuscular Disorders. 23:1044–1055CrossRef

Ballo P, Chiodi L, Cameli M, Malandrini A, Federico A, Mondillo S, Zuppiroli A (2012) Dilated cardiomyopathy and inclusion body myositis. Neurol Sci 33(2):367–370CrossRef

Finsterer J, Stöllberger C, Höftberger R (2011) Left ventricular hypertrabeculation/noncompaction in hereditary inclusion body myopathy. Int J Cardiol 150(2):e67–69CrossRef

10.

Utz W, Schmidt S, Schulz-Menger J, Luft F, Spuler S (2010) Cardiac involvement in sporadic inclusion-body myositis. Circulation 121(5):706–708CrossRef

11.

Prutkin JM, Patton KK (2009) Ventricular tachycardia in a patient with inclusion-body myositis. Pacing Clin Electrophysiol 32(12):e36–39CrossRef

12.

Krendel DA, Gilchrist JM, Bossen EH (1988) Distal vacuolar myopathy with complete heart block. Arch Neurol. 45(6):698–699CrossRef

13.

Inamori Y, Higuchi I, Inoue T, Sakiyama Y, Hashiguchi A, Higashi K, Shiraishi T, Okubo R, Arimura K, Mitsuyama Y, Takashima H (2012) Inclusion body myositis coexisting with hypertrophic cardiomyopathy: an autopsy study. Neuromuscul Disord. 22(8):747–754CrossRef

14.

Cox FM, Delgado V, Verschuuren JJ, Ballieux BE, Bax JJ, Wintzen AR, Badrising UA (2010) The heart in sporadic inclusion body myositis: a study in 51 patients. J Neurol 257(3):447–451CrossRef

15.

Marholdt H, Goedecke C, Wagner A et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258CrossRef

16.

Friedrich MG, Sechtem U, Schulz-Menger J et al (2009) International Consensus Group on cardiovascular magnetic resonance in myocarditis. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 53:1475–1478CrossRef

17.

Walcher T, Steinbach P, Spieß J et al (2011) Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Eur J Radiol 80:115–119CrossRef

18.

Yilmaz A, Gdynia HJ, Marholdt H, Sechtem U (2009) Cardiovascular magnetic resonance reveals similar damage to heart of patients with Becker and limb-girdle muscular dystrophy but no cardiac symptoms. J Magn Reson Imaging. 30:876–877CrossRef

19.

Rosenbohm A, Buckert D, Gerischer N, Walcher T, Kassubek J, Rottbauer W, Ludolph AC, Bernhardt P (2015) Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. J Neurol. 262(4):949–956CrossRef

20.

Dubowitz V, Sewry CA (2013) Histological and histochemical stains and reactions. Muscle biopsy. A practical approach. Saunders Elsevier, Philadelphia, pp 16–27

21.

Buckert D, Dewes P, Walcher T, Rottbauer W, Bernhardt P (2013) Intermediate term prognostic value of reversible perfusion deficit diagnosed by adenosine perfusion cardiac magnetic resonance imaging—a prospective follow-up study in a consecutive patient population. J Am Coll Cardiol Imaging 6:56–63CrossRef

22.

Bondarenko O, Beek AM, Hofman MB et al (2005) Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 7:481–485CrossRef

23.

Marholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H et al (2004) Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109:1250–1258CrossRef

24.

Brumback LC, Kronmal R, Heckbert SR, Ni H, Hundley WG, Lima JA, Bluemke DA (2010) Body size adjustments for left ventricular mass by cardiovascular magnetic resonance and their impact on left ventricular hypertrophy classification. Int J Cardiovasc Imaging 26:459–468CrossRef

25.

Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH (1992) Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19(7):1550–1558CrossRef

26.

Hoey ET, Pakala V, Teoh JK, Simpson H (2014) The role of imaging in hypertensive heart disease. Int J Angiol 23(2):85–92CrossRef

27.

Mavrogeni S, Katsi V, Vartela V, Noutsias M, Markousis-Mavrogenis G, Kolovou G, Manolis A (2017) The emerging role of cardiovascular magnetic resonance in the evaluation of hypertensive heart disease. BMC Cardiovasc Disord 17(1):132. https://doi.org/10.1186/s12872-017-0556-8 CrossRefPubMedPubMedCentral

28.

Themudo R, Johansson L, Ebeling-Barbier C, Lind L, Ahlström H, Bjerner T (2017) The number of unrecognized myocardial infarction scars detected at DE-MRI increases during a 5-year follow-up. Eur Radiol 27(2):715–722CrossRef

29.

Andersen K, Hennersdorf M, Cohnen M, Blondin D, Modder U, Poll LW (2009) Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Eur J Radiol 71:75–81CrossRef

30.

Díez J, González A, López B, Querejeta R (2005) Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2:209–216CrossRef

31.

Schumann CL, Jaeger NR, Kramer CM (2019) Recent advances in imaging of hypertensive heart disease. Curr Hypertens Rep 21(1):3. https://doi.org/10.1007/s11906-019-0910-6 CrossRefPubMedPubMedCentral

32.

Limaye VS, Lester S, Blumbergs P, Roberts-Thomson PJ (2010) Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus. Int J Rheum Dis 13(2):132–137CrossRef

33.

de Camargo LV, de Carvalho MS, Shinjo SK, de Oliveira ASB, Zanoteli E (2018) Clinical, histological, and immunohistochemical findings in inclusion body myositis. Biomed Res Int 2018:5069042. https://doi.org/10.1155/2018/5069042 CrossRefPubMedPubMedCentral

34.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270CrossRef

Title: Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography
Authors: Angela Rosenbohm
Dominik Buckert
Jan Kassubek
Wolfgang Rottbauer
Albert C. Ludolph
Peter Bernhardt
Publication date: 01-05-2020
Publisher: Springer Berlin Heidelberg
Keywords: Stroke
Echocardiography
Myocarditis
Echocardiography
Hypertension
Arterial Hypertension
Arterial Hypertension
Published in: Journal of Neurology / Issue 5/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09724-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Sporadic inclusion body myositis: no specific cardiac involvement in cardiac magnetic resonance tomography

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2020

Sub-angiographic peripheral emboli in high resolution DWI after endovascular recanalization

Magnetic resonance imaging in immune-mediated myelopathies

Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study

The outcome of acute functional neurological disorder: a meta-analysis of stroke-mimic presentations

Gastrointestinal dysfunction in Parkinson’s disease